Welcure Drugs & Pharmaceuticals
WELCUREDRUGSPHARMACEUTICALSLTD NSE
Welcure Drugs & Pharmaceuticals
HealthcareNSE: WELCUREDRUGSPHARMACEUTICALSLTD BSE: 524661 Pharmaceuticals
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹28.44 Cr
Volatility
Moderate
P/E Ratio
-5.5
EBITDA
₹-6.93 Cr
Return on Equity
2.12%
Debt to Equity
0
Book Value
₹0.79
52W High
₹0.89
52W Low
₹0.19
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
3- Company has reduced debt.
- Company is almost debt free.
- Stock is trading at 0.28 times its book value
Weaknesses
3- Company has low interest coverage ratio.
- Company has a low return on equity of -2.28% over last 3 years.
- Company has high debtors of 213 days.
Growth Rate
Revenue Growth
—
Net Income Growth
-350%
ROE
-116% lower than
3Y
ROCE
-109% lower than
3Y
EBITDA Margin (Avg.)
-118% lower than
3Y
Quarterly Results
| Particulars | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 | 25 | 1 | 21 | 300 | 66 | 0 | 0 |
| Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 23 | 1 | 21 | 269 | 54 | 0 | 50 |
| Operating Profit | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 31 | 11 | 0 | -50 |
| OPM % | — | — | — | — | — | — | 7% | 10% | 3% | 10% | 17% | — | — |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PBT | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 3 | 31 | 11 | 1 | -50 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 56% | 0% | 25% | 25% | 25% | 0% |
| Net Profit | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 3 | 23 | 8 | 1 | -50 |
| EPS in Rs | 0.01 | 0 | -0.01 | 0 | 0 | -0.02 | 0.01 | 0 | 0.02 | 0.19 | 0.07 | 0.01 | -0.4 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 25 | 366 |
| Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 24 | 372 |
| Operating Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | -7 |
| OPM % | 20% | 40% | 33% | -40% | 0% | -12% | 46% | 18% | — | — | 4% | -1.9% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PBT | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | -5 |
| Tax % | 0% | 0% | 0% | 0% | — | 0% | 0% | 0% | 0% | 0% | 22% | 0% |
| Net Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | -5 |
| EPS in Rs | 0 | 0.01 | 0 | 0 | 0 | 0 | 0 | 0 | 0.01 | -0.01 | 0.02 | -0.04 |
| Div. Payout % | 0% | 0% | 0% | 0% | — | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 13 | 13 | 112 | 124 |
| Reserves | -12 | -12 | -12 | -12 | -12 | -12 | -12 | -12 | -12 | -12 | -10 | -27 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 123 | 0 |
| Other Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 41 | 413 |
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 267 | 510 |
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Other Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 267 | 509 |
| Total Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 267 | 510 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -222 | 2 |
| Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 |
| Financing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 222 | 0 |
| Net Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -222 | 2 |
| CFO/OP | 100 | -125 | 67 | 50 | — | 100 | 67 | 100 | -79 | 57 | -22,890 | -25 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | — | 282 | 213 |
| Inventory Days | — | — | — | — | — | — | — | — | — | — | 2,554 | 162 |
| Days Payable | — | — | — | — | — | — | — | — | — | — | 52 | 226 |
| Cash Conversion Cycle | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | — | 2,784 | 150 |
| Working Capital Days | -876 | 36 | 81 | 73 | 46 | 0 | 0 | 0 | — | — | 2,092 | -56 |
| ROCE % | — | — | 120% | -67% | 0% | -40% | 133% | 25% | 10% | -13% | 3% | -3% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Welcure Drugs & Pharmaceuticals insights
63 extracted metrics + investor summaries across FY10–FY26.
Documents
1
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
23 Apr - Company confirmed it is not a Large Corporate for FY2026. 23 Apr - Company confirmed it is not a Large Corporate for FY2026.
2
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
15h - Company confirmed it is not a Large Corporate for FY2026. 15h - Company confirmed it is not a Large Corporate for FY2026.
3
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
3 Apr - Certificate under Regulation 74(5) of SEBI (Depository and Participants) Regulations, 2018 for the 4th Quarter and Annual year ended 31st MArch, 2026. 3 Apr - Certificate under Regulation 74(5) of SEBI (Depository and Participants) Regulations, 2018 for the 4th Quarter and Annual year ended 31st MArch, 2026.
4
Closure of Trading Window
26 Mar - Trading window closed from April 1, 2026 until 48 hours after audited results for year ended March 31, 2026. 26 Mar - Trading window closed from April 1, 2026 until 48 hours after audited results for year ended March 31, 2026.
5
Clarification sought from DLF Ltd
18h - Exchange has sought clarification from DLF Ltd on March 4, 2026, with reference to news appeared in https://www.news18.com/ dated March 4, 2026, quoting "No Water, … 18h - Exchange has sought clarification from DLF Ltd on March 4, 2026, with reference to news appeared in https://www.news18.com/ dated March 4, 2026, quoting "No Water, …
3
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer 19 Jun 2026
General_Announcements
Frequently Asked Questions about Welcure Drugs & Pharmaceuticals
What does Welcure Drugs & Pharmaceuticals Ltd do?
Incorporated in 1992, Welcure Drugs and Pharmaceuticals Ltd is in the business of pharmaceutical and healthcare.[1]
Where is Welcure Drugs & Pharmaceuticals Ltd (524661) listed?
Welcure Drugs & Pharmaceuticals Ltd trades as WELCUREDRUGSPHARMACEUTICALSLTD on the NSE and under code 524661 on the BSE.
Which sector does Welcure Drugs & Pharmaceuticals Ltd belong to?
Welcure Drugs & Pharmaceuticals Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Welcure Drugs & Pharmaceuticals Ltd?
Welcure Drugs & Pharmaceuticals Ltd has a market capitalisation of ₹28.44 Cr, which places it in the Small Cap band.
What is the PE ratio of Welcure Drugs & Pharmaceuticals Ltd?
Welcure Drugs & Pharmaceuticals Ltd trades at a PE ratio of -5.50, against a book value of ₹0.79 per share.
What is the 52-week high and low of Welcure Drugs & Pharmaceuticals Ltd?
Over the last 52 weeks Welcure Drugs & Pharmaceuticals Ltd has traded between ₹0.19 and ₹0.89.
What is the Return on Equity (ROE) of Welcure Drugs & Pharmaceuticals Ltd?
Welcure Drugs & Pharmaceuticals Ltd reported a return on equity of 2.12%. Its debt-to-equity ratio is 0.00.
Company Information
Incorporated in 1992, Welcure Drugs and Pharmaceuticals Ltd is in the business of pharmaceutical and healthcare.[1]
Face Value ₹ 1
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/524661.md for Welcure Drugs & Pharmaceuticals Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.